RxDoctor Payments Data

Jessica Rude

Family Medicine · Harpers Ferry, WVNPI 1205397478

Payments from drug & device makers

$467in general payments, 2019–2025

Across 14 payments — averaging $33.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$239
  • Novo Nordisk$94
  • Indivior Inc.$31
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$28
  • Vanda Pharmaceuticals Inc.$27
  • GSK$27
  • plus $21 from 1 others

What the payments were for

  • Food & beverage$467100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$467 in reported general payments places this provider in the 55th percentile of 843 family medicine providers in West Virginia.

See all family medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$75,659
Medicare patients
164
Services billed
1,165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$92,530
EliquisApixaban44$51,028
XareltoRivaroxaban34$40,112
JardianceEmpagliflozin28$39,718
MounjaroTirzepatide22$26,727
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$22,066
TrulicityDulaglutide18$17,354
MyrbetriqMirabegron17$9,870
SymbicortBudesonide/Formoterol Fumarate23$4,946
Albuterol Sulfate HfaAlbuterol Sulfate147$4,295
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$4,037
Advair HfaFluticasone Propion/Salmeterol11$3,566
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl21$3,415
Rosuvastatin Calcium177$3,101
Atorvastatin Calcium258$2,465

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$94$92,53077 claims
GSKTrelegy Ellipta$27$22,06628 claims
AbbVieSynthroid$239$1,56729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 843 family medicine providers in West Virginia.

Other family medicine in Harpers Ferry

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →